Sign In
Buy ROIV
$31.25
-0.180 (-0.573%)
At Close: Jun 22, 2026
Montes Archimedes Acquisition (ROIV) Upgraded to Buy: Here's What You Should Know
01:00pm, Friday, 10'th Apr 2026
Montes Archimedes Acquisition (ROIV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Capricorn Fund Managers Ltd Buys 247,000 Shares of Roivant Sciences Ltd. $ROIV
04:43am, Monday, 06'th Apr 2026
Capricorn Fund Managers Ltd raised its stake in Roivant Sciences Ltd. (NASDAQ: ROIV) by 124.4% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchan
Roivant Sciences Adds Brepocitinib LPP Trial as Batoclimab Misses Phase III TED Endpoint
01:05am, Saturday, 04'th Apr 2026
Roivant Sciences (NASDAQ: ROIV) outlined plans to expand development of its JAK1/TYK2 inhibitor brepocitinib into lichen planopilaris (LPP) and provided an update on a Phase III thyroid eye disease (T
Roivant Sciences Ltd. (ROIV) Discusses Brepocitinib Program Expansion and Phase III Batoclimab Data Update Transcript
04:32pm, Thursday, 02'nd Apr 2026
Roivant Sciences Ltd. (ROIV) Discusses Brepocitinib Program Expansion and Phase III Batoclimab Data Update Transcript
Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)
05:00am, Thursday, 02'nd Apr 2026
Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound pain, itch, and burning sensations; no FDA
Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound pain, itch, and burning sensations; no FDA
New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis
03:00pm, Saturday, 28'th Mar 2026
DURHAM, N.C., March 28, 2026 (GLOBE NEWSWIRE) -- Priovant Therapeutics, a clinical-stage biotechnology company focused on developing targeted therapeutics in autoimmune disease, announced today the pu
105,000 Shares in Roivant Sciences Ltd. $ROIV Acquired by Bamco Inc. NY
03:36am, Tuesday, 17'th Mar 2026
Bamco Inc. NY acquired a new stake in Roivant Sciences Ltd. (NASDAQ: ROIV) during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commiss
Roivant Sciences Ltd. (ROIV) Presents at Leerink Global Healthcare Conference 2026 Transcript
02:12pm, Wednesday, 11'th Mar 2026
Roivant Sciences Ltd. (ROIV) Presents at Leerink Global Healthcare Conference 2026 Transcript
First Look: Target (TGT), Paramount (PSKY) and Gold in Focus
07:38am, Wednesday, 04'th Mar 2026
Stock News Wall Street whipsawed by Mideast turmoil: The SPDR S&P 500 ETF Trust (SPY) fell Tuesday, then futures steadied as oil volatility and safeâhaven flo
Roivant Sciences Ltd. (ROIV) Discusses $2.25 Billion Global Settlement Resolving COVID Vaccine Patent Litigation Transcript
05:22am, Wednesday, 04'th Mar 2026
Roivant Sciences Ltd. (ROIV) Discusses $2.25 Billion Global Settlement Resolving COVID Vaccine Patent Litigation Transcript
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
04:15pm, Tuesday, 03'rd Mar 2026
Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna's Section 1498 appeal If the $1.3 billion payment is realized,
Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna
04:15pm, Tuesday, 03'rd Mar 2026
Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna's Section 1498 appeal If the $1.3 billion payment is realized,
Roivant Sciences Ltd. (ROIV) Presents at TD Cowen 46th Annual Health Care Conference Transcript
01:32pm, Tuesday, 03'rd Mar 2026
Roivant Sciences Ltd. (ROIV) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis
07:00am, Tuesday, 03'rd Mar 2026
FDA assigns PDUFA target action date in the third quarter of calendar year 2026 with launch expected at the end of September 2026 Priority Review supported by positive Phase 3 VALOR results, the first
